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Populations of greater sage-grouse (Centrocercus urophasianus) have declined 45–
80% in North America since 1950. Although much of this decline has been attributed to habitat
loss, recent field studies have indicated that West Nile virus (WNV) has had a significant negative
impact on local populations of grouse. We confirm the susceptibility of greater sage-grouse to
WNV infection in laboratory experimental studies. Grouse were challenged by subcutaneous
injection of WNV (103.2 plaque-forming units [PFUs]). All grouse died within 6 days of infection.
The Kaplan-Meier estimate for 50% survival was 4.5 days. Mean peak viremia for nonvaccinated
birds was 106.4 PFUs/ml (6100.2 PFUs/ml, standard error of the mean [SEM]). Virus was shed
cloacally and orally. Four of the five vaccinated grouse died, but survival time was increased (50%
survival59.5 days), with 1 grouse surviving to the end-point of the experiment (14 days) with no
signs of illness. Mean peak viremia for the vaccinated birds was 102.3 PFUs/ml (6100.6 PFUs/ml,
SEM). Two birds cleared the virus from their blood before death or euthanasia. These data
emphasize the high susceptibility of greater sage-grouse to infection with WNV.
Key words: Centrocercus urophasianus, experimental infection, greater sage-grouse,
vaccine, West Nile virus.
ABSTRACT:

ity, mortality, and risks of sage-grouse
populations to WNV infection are critical
questions to resolve to determine what
management options might be available
for the species’ conservation.
The objectives of this study were to
compare viremia and survivorship between vaccinated and nonvaccinated
greater sage-grouse subjected to experimental challenge with WNV.

INTRODUCTION

Populations of greater sage-grouse
(Centrocercus urophasianus) have declined 45–80% in North America since
1950 (Braun, 1998). It is believed that the
primary cause for population decline is
loss of habitat owing to cultivation and
overgrazing. As a consequence, Gunnison
sage-grouse (Centrocercus minimus) and
Western sage-grouse (Centrocercus urophasianus phaios) are under consideration
for listing as threatened species (United
States Fish and Wildlife Service, 2004).
Additional pressures on sage-grouse
populations have become apparent. During 2003, telemetry studies on sage-grouse
revealed unusual mortality of marked
birds. Necropsies revealed that these
clusters of mortality were attributable to
West Nile virus (WNV) infection (Naugle
et al., 2004). These observations and the
spread of WNV across the continent have
raised additional concerns among wildlife
managers relative to the well-being of
sage-grouse populations. The susceptibil-

MATERIALS AND METHODS
Study subjects

Twenty-one greater sage-grouse were
trapped in the Sheldon National Wildlife
Refuge, northwestern Nevada, USA, by the
United States Fish and Wildlife Service in
October 2003. Birds were banded, and blood
was collected from each individual via ulnar
venipuncture. The grouse were transported by
plane in 7 carriers (66335340 cm) on the
same day to Fort Collins, Colorado, USA, and
driven by truck to the United States Department of Agriculture–National Wildlife
Research Center. Upon arrival at the Research
Center, all grouse were determined to be
hatch-year birds by weight and plumage
14
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characteristics. Grouse were dusted with
DrioneH (Bayer Environmental Science, Montvale, New Jersey, USA) to control feather
mites, and wing feathers were clipped to
reduce cage trauma. Grouse were held in
captivity until experimentation (Oesterle et al.,
2005).
Experimental design

The principal goals of the experiment were
to describe the time course of infection and
survivorship in greater sage-grouse experimentally challenged with West Nile virus (WNV)
as a function of vaccination status. Nine grouse
were assigned to the nonvaccinated WNV
infection group, and 5 birds were assigned to
the vaccinated WNV infection group. One bird
was used as a negative control (i.e., sham
infection/sham vaccination).
Vaccine

A proprietary experimental DNA vaccine
was provided by Merial Ltd., Athens, Georgia,
USA. This vaccine was made by inserting the
DNA complementary to the WNV structural
genes prM and E into a fowl pox DNA
backbone. The frozen vaccine was thawed,
and 0.2 ml was diluted with 4.8 ml polymer
adjuvant (Carbopol, Merial Ltd.). Then 0.2 ml
vaccine or Carbopol was delivered subcutaneously at the inguinal fold of the left leg,
resulting in vaccination of a 107 tissue culture
infective dose (TCID50) per bird. An identical
booster vaccination was delivered 21 days after
the initial vaccination. No apparent necrosis or
other overt effects of vaccination or sham
treatment were observed.
Experimental infection

Grouse were challenged 35 days postvaccination by subcutaneous injection in the inguinal fold with 103.2 plaque-forming units
(PFUs) WNV (NY-99-6625, 1 passage in Vero
cell culture, isolated from crow brain) delivered in 0.1 ml saline. Virus was diluted in
BA-1 and titer verified by plaque assay on
Vero cells at the time of inoculation. This dose
was deemed to be within the range of
documented viral load in mosquito saliva and
was the approximate equivalent infectious
dose delivered by 1 to 6 mosquito bites
(101.3–103.8 PFU equivalents; Bunning et al.,
2002; Vanlandingham et al., 2004). During the
postinfection period, blood from grouse was
collected daily to quantify viremia (up to the
point of death, or the end-point of the
experiment, i.e., 14 days). Cloacal and oral
swabs (sterile, cotton-tipped) also were col-
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lected daily to check for shed virus and placed
in 1 ml of BA-1.
Statistical analysis

Probability of survivorship was calculated
using the Kaplan-Meier product limit estimate
for censored data, and comparison of survivorship estimates between experimental groups
(vaccinated versus not vaccinated) was made
using Cox’s F-test (StatSoft, 1999). All error
estimates are reported as 61 standard error of
the mean (SEM).
Enzyme-linked immunosorbant assays

To detect flavivirus-specific immunoglobulin M (IgM) antibodies, an IgM capture
enzyme–linked immunosorbant assay was used
(cELISA; Johnson et al., 2003). WNV positive
and negative antigens were obtained from the
Centers for Disease Control and Prevention,
Atlanta, Georgia, USA, and made following the
method of Clarke and Casals (1958). Test
samples were analyzed in duplicate, with 3
wells of control chicken serum included on
each plate. Positive-to-negative ratios (P/N)
were calculated as the mean optical density
(OD) of the test or positive control serum
wells divided by the mean OD of the negative
control serum wells. The criterion for a valid
test was a P/N for the positive control .2.0.
To detect flavivirus-specific immunoglobulin G (IgG) antibodies, an indirect ELISA
(iELISA; Ebel et al., 2002) was used. The
iELISA positive and negative antigens were
provided by the New York State Department
of Health’s Wadsworth Center Health Laboratory, Albany, New York, USA (Ebel et al.,
2001). Test samples were analyzed in duplicate, with 3 wells of control chicken serum
included on each plate. The calculation and
criterion for a positive test were as described
above.
An epitope-blocking assay (bELISA; Blitvich et al., 2003) was used to detect all WNVspecific antibodies (IgG, IgM, etc.) in a sample.
We used unlabeled monoclonal antibody
(MAb) 3.112G (Chemicon, Temecula, California), which is specifically reactive to WNV,
offers a high degree of sensitivity, and enables
the assay to be taxon-independent in its ability
to detect antibodies against WNV (Blitvich et
al., 2003). The MAb 3.112G detects the NS-1
epitope (Hall et al., 1990, 1991). Interpretation of the test was based on the following
criterion and calculation. The percentage inhibition of MAb 3.112G binding was calculated as 1002[(TS2B)/(CS2B)]3100, where TS
is the mean optical density of the test serum,
CS is the mean optical density of the control
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serum (from uninfected chickens), and B is
the background optical density. Test samples
were analyzed in duplicate, with 3 wells of
control chicken serum included on each plate.
The percentage inhibition was calculated once
the mean OD in the wells containing the
control serum samples exceeded 0.3. An
inhibition value of .30% was considered to
indicate the presence of WNV antibodies
(Blitvich et al., 2003).
Reverse transcription polymerase chain
reaction assay

WNV RNA was extracted from serum
(Lanciotti et al., 2000) and oral and cloacal
swabs (Komar et al., 2002) using the QIAampH
Viral RNA Mini Kit (QIAGEN, Valencia,
California, USA). The TaqmanH One-Step
reverse transcriptase polymerase chain reaction (RT-PCR) system (Applied Biosystems,
Foster City, California) using primers and
probes based on the published sequence of the
NY99 strain of WNV (GenBank accession
number AF196835) and the method of Lanciotti et al. (2000) were used to quantify WNV
RNA in samples.
Standard curves were generated using serial
dilutions (103) of WNV stock (107 PFUs/ml,
verified by plaque assay). RNA from each
dilution (106–1023) was extracted as described
above. In our laboratory, the detection limit of
the Applied Biosystems PCR using the TaqMan RT-PCR for WNV detection is
1021.1 PFU equivalents/ml. This is comparable to published reports by other laboratories
(Lanciotti et al., 2000). The RT-PCR method
quantifies WNV RNA in the serum sample.
Measures of viremia reported herein are in
terms of PFU equivalents based on the
conversion described above.
RESULTS

After arrival from the field (October
2003), initial serum samples indicated all
grouse were negative for flavivirus immunoglobulin G (IgG) antibodies (Fig. 1).
During April 2004, another serum sample
was obtained before vaccination treatment. Again, all birds were negative for
IgG flavivirus antibodies. Birds also tested
negative for immunoglobulin M (IgM) and
IgG antibodies to West Nile virus (WNV)
at both time intervals as determined by
the epitope-blocking assay (bELISA).
The fowl pox vaccine used in this study

FIGURE 1. Mean (6SEM) P/N for flavivirusspecific IgG antibodies as assayed by iELISA as
a function of time and vaccination status for greater
sage-grouse. Arrows indicate the date at which
vaccine or sham injection was administered. Horizontal lines depict mean (6SEM) WNV negative
chicken serum control P/N values for the iELISA.
High-titer, positive control chicken serum P/N values
(mean52.9360.20) are not shown.

did not contain the NS-1 gene of WNV. As
a consequence, we were unable to detect
the antibody response after vaccination
using the bELISA (MAb 3112.G is specific to NS-1). In its stead we used the
indirect ELISA (iELISA) to detect IgG
antibodies against WNV in the fowl pox–
vaccinated group of grouse. Twenty-one
days postvaccination, the vaccinated group
showed elevated levels for flavivirus-specific IgG antibodies (Fig. 1). The positiveto-negative (P/N) values for flavivirusspecific IgG antibodies to flavivirus remained stable at 35 days postinoculation.
However, the amount of antibody was
substantially lower than the high antibody
titer for positive control chicken serum (P/
N53.260.2). WNV antibodies in the
vaccinated group also were monitored
using the bELISA. All of these assays
were negative, consistent with interpretation that the vaccine construct included
the envelope-coding region, but not the
NS-1–coding region. The nonvaccinated
group maintained subthreshold and stable
P/N values throughout the monitoring
period (Fig. 1).
The negative control grouse survived to
the end-point of the test and maintained
normal behavior and weight; it is not
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FIGURE 2. Kaplan-Meier survival estimates (solid
lines) for vaccinated (V+) and nonvaccinated (Vo)
greater sage-grouse challenged with WNV. Dotted
lines depict 695% confidence limits.

specifically referred to in the remainder of
the study.
WNV infection caused 100% mortality
in nonvaccinated grouse (Fig. 2). Vaccinated birds survived longer than the
nonvaccinated
birds
(F 18,854.710,
P50.016). The mean Kaplan-Meier estimate for 50% survival was 9.5 days for the
vaccinated group and 4.5 days for the
nonvaccinated group. The actual mean
survival time of experimental subjects was
3.760.3 days for the nonvaccinated grouse
and 6.761.1 days for the vaccinated birds
that died. One vaccinated bird cleared the
virus from its blood but died a day later.
Another vaccinated bird cleared the virus
from its blood and survived to the endpoint of the experiment (14 days). This
grouse never showed any overt signs of
illness. The control grouse survived to the
end-point of the experiment.
Grouse that died of WNV infection all
showed similar overt signs of illness,
regardless of vaccination status. The first
signs of illness were noted during blood
sample collection. Some birds had a profuse, clear, watery, oral and nasal discharge. Shortly thereafter, the same birds
were observed to piloerect their feathers,
shiver, isolate themselves from the group,
remain immobile, and seek out walls or
other structures to rest against. Within
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hours, drooped wings, ataxia, copious oral
and nasal secretions, and labored breathing were apparent. If forced to move, the
grouse would stumble and right themselves with difficulty. During the final
stages of illness, birds would no longer
attempt to escape or were incapable of
coordinated locomotion. At this point
some birds died during sample collection;
the remaining birds were euthanized as
they were deemed to have reached the
end-point of illness. From first overt signs
of illness to the end-point took less than
6 hr.
Peak viremia occurred 3 days postinfection for the nonvaccinated group of
grouse (Table 1, Fig. 3). This coincided
with 80% of the mortality of the nonvaccinated group. Onset of oral and
cloacal shedding of viral material lagged
1 day behind initial detection of virus in
serum. The quantities of viral material
collected from swabs were higher in the
oral secretions relative to the cloacal
samples. The peak viremia for the vaccinated group was substantially lower relative to the nonvaccinated group (Fig. 3).
In addition, the viremia profile was shifted
1 day later. The pattern of oral and cloacal
shedding in the vaccinated grouse was
similar to that seen in the nonvaccinated
group (Table 1). In the 2 longest surviving
grouse, oral and cloacal shedding persisted
(7–14 days) even after the viral material
was cleared below detection limits in the
serum (7 days).
Flavivirus-specific IgM antibody was
not detected until the sixth day postinfection in any of the grouse (Fig. 4a).
Thus, in most of the nonvaccinated
grouse, no detectable flavivirus-specific
IgM antibody was present before their
death. The single grouse in the nonvaccinated group that survived to 7 days
postinfection did develop flavivirus-specific IgM antibody. For the vaccinated group
an increasing titer for flavivirus-specific
IgM antibody was observed from 6 to 9
days postinfection. After 9 days, the titer
was stable.
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TABLE 1. Concentration of West Nile virus in specimens as a function of vaccination status and time
since infection.
Nonvaccinated group
Serum
Day Nb nc

Xd

0
1
2
3
4
5
6
7
8
9
10
11
12
13
14

nd
1.7
5.4
6.4
5.9
6.1
6.1

9
9
9
8
2
1
1

9
9
9
8
2
1
1

a

Oral
6SE n

—
0.2
0.3
0.2
0.2
0.0
0.0

0
0
9
8
2
1
1

a

Vaccinated group
Cloacal

X

6SE

n

X

nd
nd
1.1
3.1
3.1
4.8
5.4

—
—
0.3
0.3
0.7
—
—

0
0
9
8
2
1
1

—
—
2.0
2.9
2.2
3.8
3.8

a

Serum

6SE N

—
—
0.3
0.3
0.4
—
—

5
5
5
5
5
4
4
4
2
2
1
1
1
1
1

Oral

Cloacal

n

X

6SE

n

X

6SE

n

X

6SE

0
4
5
5
5
4
4
4
1
0
0
0
0
0
0

nd
20.1
0.0
1.3
2.3
1.2
1.2
0.9
20.3
nd
nd
nd
nd
nd
nd

—
0.6
0.6
0.9
0.6
0.4
0.2
0.2
0.0
—
—
—
—
—
—

0
0
1
5
5
4
3
4
2
2
1
1
0
1
1

nd
nd
21.0
0.1
1.2
1.9
1.7
1.8
1.6
0.9
0.2
0.3
nd
20.4
20.9

—
—
0.0
0.5
0.8
0.5
1.1
1.1
1.2
0.9
0.0
0.0
—
0.0
0.0

0
0
0
2
4
3
3
4
2
1
1
1
0
1
1

nd
nd
nd
0.3
0.3
0.9
0.4
0.3
20.1
20.4
20.3
0.4
nd
20.7
20.7

—
—
—
0.4
0.7
0.9
0.5
0.2
1.1
0.0
0.0
0.0
—
0.0
0.0

a

Mean (X) censored quantity of West Nile virus detected in serum, oral swabs, and cloacal swabs6standard error (SE),
expressed as Log10(PFUs/ml).

b

N is the number of birds tested. Sample sizes less than 9 for the nonvaccinated group and 5 for the vaccinated group
reflect mortality.

c

n is the number of birds with detectable virus. Assay detection limit was 0.1 PFUs/ml, where PFU is plaque-forming
unit. Values below threshold are listed as ‘‘nd’’ in the table.

d

X5SPFUsi/n, where PFUs is the quantity of virus detected in the i-th individual.

Flavivirus-specific IgG antibody never
rose above threshold in the nonvaccinated
grouse (Fig. 4b). Levels of flavivirusspecific IgG antibody in the vaccinated
group were slightly elevated at the onset of
the experimental infection relative to
negative control serum (Fig. 1) but did
not rise above threshold until 9 days
postinfection. By this time only 2 of the
5 birds were alive in the vaccinated group.
The bELISA appeared to be less
sensitive than the capture enzyme–linked
immunosorbant assay (cELISA) for IgM
(Fig. 4a, c). Values above the preinfection
baseline appeared to lag the cELISA by 2
days. This lag most likely represents
detection of WNV-specific IgM antibody
by the bELISA because the iELISA did
not reach suprathreshold value until 9
days postinfection (Fig. 4b, c).

DISCUSSION

Greater sage-grouse are highly susceptible to West Nile virus (WNV) infection.
These experimental data not only confirm
field studies documenting the susceptibility of greater sage-grouse to WNV (Naugle
et al., 2004), but emphasize the rapidity
with which the virus affects grouse. It
appears that once a sage-grouse becomes
infected there is little to no chance of
surviving. With the spread of WNV into
sage-grouse habitat throughout the western USA, this observation does not bode
well for the long-term conservation of this
species.
Viremia developed at a similar pace in
greater sage-grouse relative to bird species
deemed to be highly susceptible to WNV
infection, for example, corvids (Fig. 5;
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FIGURE 3. Mean (6SEM) viremia, as indicated by RT-PCR, as a function of time and vaccination status
for greater sage-grouse challenged with WNV. Dashed line depicts the detection limit (1021.1 PFUs/ml) for
the RT-PCR method. Numerical insets indicate the number of grouse alive and sampled for RT-PCR analysis
of serum. Graphical insets depict individual viremia profiles for vaccinated and nonvaccinated groups.

Turell et al., 2003; Komar et al., 2003;
Weingartl et al., 2004). Peak viremia for
sage-grouse was well within the median
range for peak viremia reported for other
species (Fig. 5). Although data on mortality rates for other species of birds are few,
greater sage-grouse should be considered
a highly susceptible species among birds
since all greater sage-grouse died after
being experimentally infected with WNV.
Of the 25 species of birds experimentally
infected by Komar et al. (2003), 8 showed
mortality, and 4 of these showed 100%
mortality: American crow (Corvus brachyrhynchos), black-billed magpie (Pica
hudsonia), ring-billed gull (Larus delawarensis), and house finch (Carpodacus
mexicanus). Mortality was high for other
species as well (33–75%). For the most
susceptible species, the mean time to
mortality was 6.860.8 days until death

(Komar et al., 2003). The mean time until
death for greater sage-grouse was 3.760.3
days.
Preliminary histological studies indicate
that the virus was located throughout the
major organs (Cynthia Smeraski and Larry
Clark, unpubl.). Gross necropsy showed
no overt signs of organ damage. Given the
copious oral and nasal secretions and
labored breathing, it appears that the
cause of death may be related to congestive heart failure or pulmonary edema.
Although the number of greater sagegrouse available for the vaccination studies
was initially limited and the success, in
terms of survivorship, was low, there is
room for optimism. Two vaccinated birds
cleared the virus from their blood, and 1
bird survived to the end-point of the
experiment. This bird was apparently in
good condition, having normal behavior

20

JOURNAL OF WILDLIFE DISEASES, VOL. 42, NO. 1, JANUARY 2006

FIGURE 5. Comparison of viremia profiles for
greater sage-grouse (solid circles), chickens (open
circles), and 25 other species of birds (bars)
challenged with WNV. Boxes encompass the 25th
and 75th percentiles of mean values reported by
Komar et al. (2003). Capped vertical lines encompass
the 10th and 90th percentiles of viremia, and dashes
encompass the 5th and 95th percentiles of viremia
values reported for the 25 species of birds. Horizontal lines depict the median viremia for the 25 species.
Viremia profile for the chicken was adapted from
Langevin et al. (2001).
FIGURE 4. Mean (6SEM) antibody to WNV in
greater sage-grouse serum as a function of ELISA
assay and time. (a) cELISA detects IgM, (b) iELISA
detects IgG, and (c) bELISA detects IgM and IgG
antibodies to WNV. Horizontal dashed lines depict
the threshold value for each assay.

and weight. Vaccinated grouse had lower
viremia relative to nonvaccinated grouse,
and the peak viremia for the vaccinated
group was delayed by 1 day. Together
these patterns indicate that the vaccine
was successful in immunizing the birds,
allowing them to clear the virus from the
blood. However, because of persistent
cloacal and oral shedding (Table 1) and
initial immunohistochemical analysis indicating pervasive infection of tissue, it
appears that the DNA vaccine was only
partially effective at clearing the virus
from all tissue.
Grouse in the nonvaccinated group died
before an antibody response was detected.
Vaccinated grouse seroconverted for flavirus immunoglobulin G (IgG). This was
a precondition for the subsequent experimental inoculations. However, the posi-

tive to negative ratio (P/N) (indirect
ELISA [iELISA]) was lower than observed in the high-titer positive control
chicken serum, suggesting that improvements could be made in stimulating the
antibody response. Nonetheless, even the
relatively weak antibody response to vaccination apparently was sufficient to allow
grouse to survive to the point where
further antibody response was apparent
after WNV challenge. Therefore, grouse in
the vaccinated group were better able to
clear the virus from their blood and
survived longer relative to the nonvaccinated group. Thus, the vaccine approach
shows promise as a conservation tool, and
several possibilities exist to increase the
efficacy of the vaccinations. Increased
immunoprotection may be gained by
adding the NS1 gene of WNV to the fowl
pox. NS1 has been shown to be an
important immunogen in other systems
and could be added to the vaccine
construct relatively easily (Hall et al.,
2003). The goal would be not only to clear
virus from the blood, but also to decrease
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the viral load in other tissue. Increasing
the efficacy of the vaccine may be possible
by using different adjuvants, diluents, or
vaccination regimes as well.
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